Tianjin Zhongxin Pharmaceutical Group Corp Ltd
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited engages in the research, development, processing, manufacturing, and sale of traditional Chinese medicine in China. It provides pharmaceutical products for cardiovascular and cerebrovascular, skin wound repair, health preservation, respiratory, digestion, rheumatism and osteodynia, urological, gynecological and pediatric, ophthalmologic… Read more
Market Cap & Net Worth: Tianjin Zhongxin Pharmaceutical Group Corp Ltd (600329)
Tianjin Zhongxin Pharmaceutical Group Corp Ltd (SHG:600329) has a market capitalization of $3.23 Billion (CN¥23.72 Billion) as of March 18, 2026. Listed on the SHG stock exchange, this China-based company holds position #4468 globally and #457 in its home market, demonstrating a 1.46% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Tianjin Zhongxin Pharmaceutical Group Corp Ltd's stock price CN¥41.60 by its total outstanding shares 570094356 (570.09 Million).
Tianjin Zhongxin Pharmaceutical Group Corp Ltd Market Cap History: 2015 to 2026
Tianjin Zhongxin Pharmaceutical Group Corp Ltd's market capitalization history from 2015 to 2026. Data shows growth from $1.46 Billion to $3.23 Billion (9.11% CAGR).
Tianjin Zhongxin Pharmaceutical Group Corp Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Tianjin Zhongxin Pharmaceutical Group Corp Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.33x
Tianjin Zhongxin Pharmaceutical Group Corp Ltd's market cap is 0.33 times its annual revenue
1.02x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
1.07x
Tianjin Zhongxin Pharmaceutical Group Corp Ltd's market cap is 1.07 times its annual earnings
10.35x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.46 Billion | $7.08 Billion | $451.44 Million | 0.21x | 3.23x |
| 2016 | $1.22 Billion | $6.24 Billion | $423.60 Million | 0.19x | 2.87x |
| 2017 | $1.05 Billion | $5.69 Billion | $476.08 Million | 0.18x | 2.20x |
| 2018 | $883.36 Million | $6.36 Billion | $561.68 Million | 0.14x | 1.57x |
| 2019 | $999.31 Million | $6.99 Billion | $625.57 Million | 0.14x | 1.60x |
| 2020 | $1.28 Billion | $6.60 Billion | $661.70 Million | 0.19x | 1.94x |
| 2021 | $2.33 Billion | $6.91 Billion | $769.14 Million | 0.34x | 3.03x |
| 2022 | $2.21 Billion | $8.25 Billion | $861.79 Million | 0.27x | 2.57x |
| 2023 | $2.61 Billion | $8.22 Billion | $986.71 Million | 0.32x | 2.65x |
| 2024 | $2.39 Billion | $7.31 Billion | $2.23 Billion | 0.33x | 1.07x |
Competitor Companies of 600329 by Market Capitalization
Companies near Tianjin Zhongxin Pharmaceutical Group Corp Ltd in the global market cap rankings as of March 18, 2026.
Key companies related to Tianjin Zhongxin Pharmaceutical Group Corp Ltd by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Tianjin Zhongxin Pharmaceutical Group Corp Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Tianjin Zhongxin Pharmaceutical Group Corp Ltd's market cap moved from $1.46 Billion to $ 3.23 Billion, with a yearly change of 9.11%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥3.23 Billion | -8.81% |
| 2025 | CN¥3.54 Billion | +48.12% |
| 2024 | CN¥2.39 Billion | -8.47% |
| 2023 | CN¥2.61 Billion | +18.15% |
| 2022 | CN¥2.21 Billion | -5.20% |
| 2021 | CN¥2.33 Billion | +81.66% |
| 2020 | CN¥1.28 Billion | +28.59% |
| 2019 | CN¥999.31 Million | +13.13% |
| 2018 | CN¥883.36 Million | -15.56% |
| 2017 | CN¥1.05 Billion | -14.02% |
| 2016 | CN¥1.22 Billion | -16.52% |
| 2015 | CN¥1.46 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Tianjin Zhongxin Pharmaceutical Group Corp Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.23 Billion USD |
| MoneyControl | $3.23 Billion USD |
| MarketWatch | $3.23 Billion USD |
| marketcap.company | $3.23 Billion USD |
| Reuters | $3.23 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.